Therapy Detail

Therapy Name Toca 511 + Toca FC
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Toca 511 T5.0002 Chemotherapy - Antimetabolite 10 Toca 511 is a retroviral vector encoding yeast cytosine deaminase, which converts the prodrug flucytosine into 5-fluorouracil upon infection of tumor cells, leading to tumor cell death (PMID: 22547150).
Toca FC Chemotherapy - Antimetabolite 10 Toca FC is an extended release form of flucytosine, which inhibits DNA synthesis after conversion to 5-fluorouracil (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown malignant glioma not applicable Toca 511 + Toca FC Phase Ib/II Actionable In a Phase I trial, Toca 511 and Toca FC combination treatment resulted in complete response in 3 and partial response in 2 patients with recurrent high-grade glioma, with a median duration of response of 25.2 months (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A085; NCT01470794). detail...
Unknown unknown malignant glioma not applicable Toca 511 + Toca FC Phase I Actionable In a Phase I trial, Toca 511 and Toca FC demonstrated safety and preliminary efficacy, with median overall survival ranging from 12.1 to 13.6 months in patients with recurrent high grade glioma (Neuro Oncol (2016) 18 (suppl 6): vi18.; NCT02414165). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02414165 Phase II Bevacizumab Lomustine Toca 511 + Toca FC Temozolomide P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5) Active, not recruiting
NCT01156584 Phase I Toca 511 + Toca FC A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma Completed
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Active, not recruiting